Ivonescimab plus chemotherapy before surgery for resectable esophageal squamous cell cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2, single-arm trial evaluating neoadjuvant Ivonescimab (AK112) combined with chemotherapy for patients with resectable esophageal squamous cell carcinoma. Participants receive Ivonescimab with albumin-bound paclitaxel and carboplatin before undergoing esophagectomy. The goal is to see if this perioperative strategy can improve tumor control and potentially survival by addressing systemic disease and local tumor burden. Safety, feasibility, and preliminary signals of efficacy will be assessed through surgical outcomes and pathological responses. The study is conducted at a single center in China and targets adults with localized disease who are candidates for curative resection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. signed informed consent;
2. patients age 18 to 75 years old
3. primary resectable, histologically confirmed esophageal squamous cell cancer;
4. Esophageal squamous cell carcinoma the clinical stage was II-IVA (according to AJCC TNM stage, 8th edition).
5. ECOG PS 0-1.
6. No distant metastasis, the diseases could be resectable assessed by thoracic oncologist;

Exclusion Criteria:

1. with significant cardiovascular disease;
2. current treatment with anti-viral therapy or HBV;
3. Female patients who are pregnant or lactating;
4. history of malignancy within 5 years prior to screening;
5. active or history of autoimmune disease or immune deficiency;
6. signs of distant metastases.

Where it's running

• The Second Affiliated Hospital of Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Zixiang Wu, M.D
• Email: zixiang0717@zju.edu.cn
• Phone: +8615268156132

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camrelizumab, chemotherapy and Ivarmacitinib before surgery for resectable esophageal squamous cell carcinoma

  This trial tests whether giving camrelizumab with chemotherapy and the JAK inhibitor Ivarmacitinib before surgery can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma that can be removed by operation.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, China · NCT07505186

• Ivonescimab with albumin‑paclitaxel and cisplatin before surgery for esophageal squamous cell carcinoma

  This trial tests whether adding ivonescimab to albumin‑paclitaxel and cisplatin before surgery helps people with resectable, locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 1/2 Tang-Du Hospital · Xi'an, Shannxi · NCT07385001

• Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific

  This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07359040

• Envafolimab with albumin-bound paclitaxel and carboplatin before surgery for resectable locally advanced esophageal squamous cell carcinoma

  This study tests whether adding envafolimab to albumin-bound paclitaxel and carboplatin before surgery helps people with resectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07266493

• Ivonescimab with short-course hypofractionated radiotherapy for second-line esophageal squamous cell carcinoma

  This will try Ivonescimab plus a short course of higher‑dose radiotherapy as a second‑line option for adults (18–80) with locally advanced or metastatic esophageal squamous cell carcinoma who have failed first‑line therapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07188103

• Neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma

  This study is testing two different treatment plans for people with advanced esophageal cancer to see which one works better and is safer before surgery.

  Recruiting Phase 2/3 Army Medical Center of PLA · Chongqing, None Selected · NCT06354530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.